Since 2015, French biotechnology company Poeitis has been co-developing its 3D laser-assisted bioprinting technology to fabricate skin models. Now BASF, the largest chemicals producer in the world, will be helping Poeitis develop the technology for new services in the cosmetics industry.
Mimeskin is BASF’s answer for synthetic skin. As such, the first stage of the Poeitis agreement will focus on developing automated production of Mimeskin models, adding to R&D intelligence gained in a previous project with BASF. Afterwards, the collaborators will work on adding more complexity to the models, adding new cell types such as pigment producing melanocytes or hair cells.
Sebastien Cadau, head of tissue engineering development at BASF, explains, “During our cooperation, we gained important insights like the parameters and kinetics of dermis maturation. A mature and thick dermis is an essential condition to obtain optimum results in epidermal printing.”
Entering the commercial market
Since September 2016 Poeitis has been working with L’Oréal cosmetics to develop 3D bioprinted hair. Biotechnology competitor Organovo has also been working with the French cosmetics giant in efforts to fabricate skin tissue. However a sharp decline in Organovo’s share-price and having a sizeable proportion of their workforce redundant has added to concerns about the company.
BASF’s intention is to bring several new skin therapy treatments to market “in the coming years.” In relation to BASF, Bruno Brisson, Poietis Co-Founder and Vice President of Business Development, concludes, “This agreement confirms a fruitful scientific collaboration and strengthens our partnership with the leading ingredients manufacturer for the personal care market.”
“This is a formal recognition of Poietis’ unique technology and its valorization driven by new developments since the creation of the company.”
https://3dprintingindustry.com/news/basf-signs-3d-bioprinting-cosmetics-deal-poeitis-123313/
this is nothing ground breaking, but we know they wont have to worry about running into financing problems with L'Oreal and BASF backing them up. I also read Poeitis increased their staff from 15 or so members to 25 this year. Maybe they will be able to increase it even more now. hopefully we can get an interview with Poeitis, would love to see where they stand.
Mimeskin is BASF’s answer for synthetic skin. As such, the first stage of the Poeitis agreement will focus on developing automated production of Mimeskin models, adding to R&D intelligence gained in a previous project with BASF. Afterwards, the collaborators will work on adding more complexity to the models, adding new cell types such as pigment producing melanocytes or hair cells.
Sebastien Cadau, head of tissue engineering development at BASF, explains, “During our cooperation, we gained important insights like the parameters and kinetics of dermis maturation. A mature and thick dermis is an essential condition to obtain optimum results in epidermal printing.”
Entering the commercial market
Since September 2016 Poeitis has been working with L’Oréal cosmetics to develop 3D bioprinted hair. Biotechnology competitor Organovo has also been working with the French cosmetics giant in efforts to fabricate skin tissue. However a sharp decline in Organovo’s share-price and having a sizeable proportion of their workforce redundant has added to concerns about the company.
BASF’s intention is to bring several new skin therapy treatments to market “in the coming years.” In relation to BASF, Bruno Brisson, Poietis Co-Founder and Vice President of Business Development, concludes, “This agreement confirms a fruitful scientific collaboration and strengthens our partnership with the leading ingredients manufacturer for the personal care market.”
“This is a formal recognition of Poietis’ unique technology and its valorization driven by new developments since the creation of the company.”
https://3dprintingindustry.com/news/basf-signs-3d-bioprinting-cosmetics-deal-poeitis-123313/
this is nothing ground breaking, but we know they wont have to worry about running into financing problems with L'Oreal and BASF backing them up. I also read Poeitis increased their staff from 15 or so members to 25 this year. Maybe they will be able to increase it even more now. hopefully we can get an interview with Poeitis, would love to see where they stand.
